Online Management of Breast Diseases Patient Education |  Physician Guidelines |  Treatment Index
News |  TransMed |  E-Mail |  Disclaimer

Onc.Protocol: AC

 

 

ONCOLOGIC PROTOCOL

Classical CMF

Cyclophosphamide & Methotrexate & 5-Florouracil

MAJOR INDICATIONS: TREATMENT FOR STAGE I, II & III (A&B) BREAST CANCERS
IDENTIFICATION: Combination chemotherapy with cyclophosphamide (Cytoxan), methotrexate and florouracil (5FU); also called "Classical CMF".
These drugs have been approved by the FDA (Food and Drug Administration) for the treatment of breast cancer.
DOSES: Cyclophosphamide 100 mg/M2, Methotrexate 40 mg/M2, Florouracil 600 mg/M2
ROUTE: Intravenous (IV) methotrexate and 5FU. Oral cytoxan
DURATION AND TIMING: Cytoxan is given for 14 days in a row orally; methotrexate and 5FU are given the first day and repeated one week later. The treatments are repeated every 28 days for 6 treatments (6 months).
Possible Side effects:
  • Hematopoetic: decrease in blood cells, especially white cells (neutropenia) but also red cells (anemia) and/or platelets (thrombocytopenia).
  • Gastrointestinal: possible nausea and vomiting (which may be decreased or prevented with medications); diarrhea; mouth sores; decreased appetite.
  • Integmentary: moderate to severe hair loss; dry skin, nail thinning or ridging.
  • Genitourinary: cytoxan may cause irritation to the kidneys or bladder.
  • Fertility: cytoxan may cause damage to the ovaries of premenopausal women. This may lead to temporary or permanent infertility. Patients may also develop an early menopause.
  • Cardiovascular: rare instances of irregular heart beats or chest discomfort have been attributed to 5FU (risk is increased in those with underlying heart disease).
  • Neurological: some patients complain of a decrease in their ability to concentrate and/or remember, which improves on completion of therapy.
  • Other: some patients complain of taste changes and/or lack of appetite.

Back gif

 

1997 - TransMed Network